AIMS:To identify the clinical and histological characteristics of ROS1-rearranged non-small-cell lung carcinomas (NSCLCs) and build a prediction model to prescreen suitable patients for molecular testing. METHODS AND RESULTS:We identified 27 cases of ROS1-rearranged lung adenocarcinomas in 1165 patients with NSCLCs confirmed by real-time PCR and FISH and performed univariate and multivariate analyses to identify predictive factors associated with ROS1 rearrangement and finally developed prediction model. Detected with ROS1 immunochemistry, 59 cases of 1165 patients had a certain degree of ROS1 expression. Among these cases, 19 cases (68%, 19/28) with 3+ and 8 cases (47%, 8/17) with 2+ staining were ROS1 rearrangement verified by real-time P...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
ROS1 rearrangement characterizes a small subset (1%–2%) of non-small cell lung cancer and is associa...
ROS proto-oncogene 1 (ROS1) rearrangements are reported in about 1–2% of non-squamous non-small-cell...
Introduction: We sought to evaluate the clinical and pathological characteristics of patients with n...
IntroductionWe sought to evaluate the clinical and pathological characteristics of patients with non...
BACKGROUND: ROS1 rearrangement accounts for 1%-2% of non-small cell lung cancer (NSCLC) with a remar...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
<div><p><i>ROS1</i> rearrangement is a predictive biomarker for response to the tyrosine kinase inhi...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
To evaluate the frequency and clinicopathological features of ROS1 and RET rearrangements in N2 node...
<div><p>To evaluate the frequency and clinicopathological features of <i>ROS1</i> and <i>RET</i> rea...
AIMS: To assess the prevalence of ROS1 rearrangements in a retrospective and prospective diagnostic ...
Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of...
ROS1 gene rearrangements are reported in 1–2% of lung adenocarcinomas (ACA) and are associated with ...
Aims. To assess the prevalence of ROS1 rearrangements in a retrospective and prospective diagnostic ...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
ROS1 rearrangement characterizes a small subset (1%–2%) of non-small cell lung cancer and is associa...
ROS proto-oncogene 1 (ROS1) rearrangements are reported in about 1–2% of non-squamous non-small-cell...
Introduction: We sought to evaluate the clinical and pathological characteristics of patients with n...
IntroductionWe sought to evaluate the clinical and pathological characteristics of patients with non...
BACKGROUND: ROS1 rearrangement accounts for 1%-2% of non-small cell lung cancer (NSCLC) with a remar...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
<div><p><i>ROS1</i> rearrangement is a predictive biomarker for response to the tyrosine kinase inhi...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
To evaluate the frequency and clinicopathological features of ROS1 and RET rearrangements in N2 node...
<div><p>To evaluate the frequency and clinicopathological features of <i>ROS1</i> and <i>RET</i> rea...
AIMS: To assess the prevalence of ROS1 rearrangements in a retrospective and prospective diagnostic ...
Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of...
ROS1 gene rearrangements are reported in 1–2% of lung adenocarcinomas (ACA) and are associated with ...
Aims. To assess the prevalence of ROS1 rearrangements in a retrospective and prospective diagnostic ...
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotin...
ROS1 rearrangement characterizes a small subset (1%–2%) of non-small cell lung cancer and is associa...
ROS proto-oncogene 1 (ROS1) rearrangements are reported in about 1–2% of non-squamous non-small-cell...